NanoVibronix, Inc.

Equities

NAOV

US63008J6038

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:30:00 2024-04-18 pm EDT 5-day change 1st Jan Change
0.75 USD 0.00% Intraday chart for NanoVibronix, Inc. -5.06% -34.78%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
NanoVibronix, Inc. Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity CI
NanoVibronix, Inc. Signs Research Agreement for Clinical Study of UroShield with University of Michigan CI
NanoVibronix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Investors Eye Fed Moves as US Futures Trend Lower in Friday's Premarket MT
NanoVibronix, Inc. Gains Approval for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff CI
NanoVibronix Files Registration Statement on Behalf of Selling Shareholders MT
NanoVibronix to Raise $5 Million Through Securities Placement MT
Top Midday Gainers MT
NanoVibronix, Inc. announced that it expects to receive $5 million in funding CI
NanoVibronix Says It's Working to Understand Implications of CMS Decision Related to PainShield Device MT
NanoVibronix, Inc. Applies for Inclusion of Uroshield Products in Nhs Prescription Services' Drug Tariff CI
NanoVibronix Extends Distribution Agreement With Ultra Pain Products for Ultrasound Therapy Devices; Shares Rise MT
NanoVibronix Extends Distribution Agreement with Its Largest Distributor for PainShield and PainShield Plus CI
NanoVibronix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
NanoVibronix Announces Distribution Agreement with Mio-Guard CI
NanoVibronix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
NanoVibronix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
NanoVibronix, Inc. Receives Positive Final Results of Independent Lifecycle Testing of PainShield Prompted by Centers for Medicare and Medicaid Services CI
NanoVibronix Files Provisional Patent Application in US for UroShield Ultra; Shares Jump MT
NanoVibronix, Inc. Files Provisional U.S. Patent Application for UroShield Ultra CI
Nanovibronix, Inc. Announces Positive Results from Independent Product Trial of UroShield for Patients with A Spinal Cord Injury CI
NanoVibronix Regains Nasdaq Compliance for Listing MT
Sector Update: Health Care Stocks Mostly Remain Mixed Late Wednesday MT
Sector Update: Health Care MT
Chart NanoVibronix, Inc.
More charts
NanoVibronix, Inc. is a medical device company. The Company is focused on developing noninvasive biological response-activating devices utilizing its low-intensity surface acoustic wave (SAW) technology. Its primary products consist of UroShield and PainShield. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use, which markets in the United States under Food and Drug Administration (FDA) policy of enforcement discretion during the COVID-19 pandemic and is undergoing clinical testing. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. Its PainShield family of products includes PainShield MD and PainShield Plus.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. NAOV Stock
  4. News NanoVibronix, Inc.
  5. Earnings Flash (NAOV) NANOVIBRONIX Posts Q3 Revenue $499,000